Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass.
Latham
P
P
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, 75235-9068, USA.
Revelis
A F
AF
Joshi
G P
GP
DiMaio
J M
JM
Jessen
M E
ME
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D017809:Fatal Outcome; D019918:Heart Valve Prosthesis Implantation; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D009102:Multiple Organ Failure; D010314:Partial Thromboplastin Time; D011183:Postoperative Complications; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D013927:Thrombosis / Q000139:chemically induced* / Q000150:complications
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin